# Clinical Trials Data EGFR - Document 105

# RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough

## Clinical Trial: https://clinicaltrials.gov/study/NCT01805362

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Chronic kidney disease stage 3 to 4,\n\* ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or irbesartan) on awaking for at least three months,\n\* History of hypertension or proteinuria \\> 0,5 g/24h or g/g creatininuria,\n\* Adult with social security insurance,\n\* Informed consent signed.\n\nExclusion Criteria:\n\n\* Office blood pressure \u2265 160/100 mmHg,\n\* Pathology with life expectancy \\< 1 year,\n\* Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics (modamide, amiloride), or direct renin inhibitor.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention EGFR gene mutation status as either an inclusion or exclusion criterion. Therefore, having an EGFR mutation \*doesn't automatically disqualify\* a patient, but it also doesn't guarantee eligibility. They would need to meet all other inclusion criteria and not meet any of the exclusion criteria to be considered.